These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1797 related articles for article (PubMed ID: 22591293)

  • 41. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.
    Yousry TA; Pelletier D; Cadavid D; Gass A; Richert ND; Radue EW; Filippi M
    Ann Neurol; 2012 Nov; 72(5):779-87. PubMed ID: 23280794
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Natalizumab treatment for multiple sclerosis: updates and considerations for safer treatment in JCV positive patients.
    Nali LH; Moraes L; Fink MC; Callegaro D; Romano CM; Oliveira AC
    Arq Neuropsiquiatr; 2014 Dec; 72(12):960-5. PubMed ID: 25465776
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.
    Blinkenberg M; Sellebjerg F; Leffers AM; Madsen CG; Sørensen PS
    Mult Scler; 2013 Aug; 19(9):1226-9. PubMed ID: 23508652
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.
    Boster AL; Nicholas JA; Topalli I; Kisanuki YY; Pei W; Morgan-Followell B; Kirsch CF; Racke MK; Pitt D
    JAMA Neurol; 2013 Mar; 70(3):398-402. PubMed ID: 23338729
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1.
    Bozic C; Richman S; Plavina T; Natarajan A; Scanlon JV; Subramanyam M; Sandrock A; Bloomgren G
    Ann Neurol; 2011 Nov; 70(5):742-50. PubMed ID: 22162056
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
    Rudick RA; Stuart WH; Calabresi PA; Confavreux C; Galetta SL; Radue EW; Lublin FD; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA; Sandrock AW;
    N Engl J Med; 2006 Mar; 354(9):911-23. PubMed ID: 16510745
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis.
    Warnke C; Mausberg AK; Stettner M; Dehmel T; Nekrich L; Meyer zu Horste G; Hartung HP; Fogdell-Hahn A; Adams O; Kieseier BC
    Neurology; 2013 Oct; 81(16):1400-8. PubMed ID: 24049136
    [TBL] [Abstract][Full Text] [Related]  

  • 48. John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis.
    Kapica-Topczewska K; Collin F; Tarasiuk J; Czarnowska A; Chorąży M; Mirończuk A; Kochanowicz J; Kułakowska A
    Eur Neurol; 2020; 83(5):487-492. PubMed ID: 33027785
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.
    Langer-Gould A; Atlas SW; Green AJ; Bollen AW; Pelletier D
    N Engl J Med; 2005 Jul; 353(4):375-81. PubMed ID: 15947078
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Switching from natalizumab to fingolimod: an observational study.
    Sempere AP; Martín-Medina P; Berenguer-Ruiz L; Pérez-Carmona N; Sanchez-Perez R; Polache-Vengud J; Feliu-Rey E
    Acta Neurol Scand; 2013 Aug; 128(2):e6-e10. PubMed ID: 23336398
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Natalizumab for relapsing-remitting multiple sclerosis.
    Horga A; Tintoré M
    Neurologia; 2011; 26(6):357-68. PubMed ID: 21193250
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.
    Yousry TA; Major EO; Ryschkewitsch C; Fahle G; Fischer S; Hou J; Curfman B; Miszkiel K; Mueller-Lenke N; Sanchez E; Barkhof F; Radue EW; Jäger HR; Clifford DB
    N Engl J Med; 2006 Mar; 354(9):924-33. PubMed ID: 16510746
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.
    Basnyat P; Hagman S; Kolasa M; Koivisto K; Verkkoniemi-Ahola A; Airas L; Elovaara I
    Mult Scler Relat Disord; 2015 Jul; 4(4):334-8. PubMed ID: 26195052
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
    Fine AJ; Sorbello A; Kortepeter C; Scarazzini L
    Ann Neurol; 2014 Jan; 75(1):108-15. PubMed ID: 24242357
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.
    Kleinschmidt-DeMasters BK; Tyler KL
    N Engl J Med; 2005 Jul; 353(4):369-74. PubMed ID: 15947079
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance.
    Blair NF; Brew BJ; Halpern JP
    Neurology; 2012 Feb; 78(7):507-8. PubMed ID: 22302545
    [No Abstract]   [Full Text] [Related]  

  • 57. Changes to anti-JCV antibody levels in a Swedish national MS cohort.
    Warnke C; Ramanujam R; Plavina T; Bergström T; Goelz S; Subramanyam M; Kockum I; Rahbar A; Kieseier BC; Holmén C; Olsson T; Hillert J; Fogdell-Hahn A
    J Neurol Neurosurg Psychiatry; 2013 Nov; 84(11):1199-205. PubMed ID: 23463870
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
    Muñoz-Culla M; Irizar H; Castillo-Triviño T; Sáenz-Cuesta M; Sepúlveda L; Lopetegi I; López de Munain A; Olascoaga J; Baranzini SE; Otaegui D
    Mult Scler; 2014 Dec; 20(14):1851-9. PubMed ID: 24852919
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients.
    Rossi F; Newsome SD; Viscidi R
    Mol Cell Probes; 2015 Feb; 29(1):54-62. PubMed ID: 25483260
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France.
    Vukusic S; Rollot F; Casey R; Pique J; Marignier R; Mathey G; Edan G; Brassat D; Ruet A; De Sèze J; Maillart E; Zéphir H; Labauge P; Derache N; Lebrun-Frenay C; Moreau T; Wiertlewski S; Berger E; Moisset X; Rico-Lamy A; Stankoff B; Bensa C; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Vaillant M; Cabre P; Montcuquet A; Wahab A; Camdessanché JP; Tourbah A; Guennoc AM; Hankiewicz K; Patry I; Nifle C; Maubeuge N; Labeyrie C; Vermersch P; Laplaud DA;
    JAMA Neurol; 2020 Jan; 77(1):94-102. PubMed ID: 31479149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 90.